Literature DB >> 11231598

Countering the 'counterattack' hypothesis.

N P Restifo.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11231598      PMCID： PMC1955757          DOI： 10.1038/85357

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  11 in total

1.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

2.  Immune privilege or inflammation? Insights into the Fas ligand enigma.

Authors:  J O'Connell; A Houston; M W Bennett; G C O'Sullivan; F Shanahan
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

3.  Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.

Authors:  J Allison; H M Georgiou; A Strasser; D L Vaux
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

4.  Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction.

Authors:  S M Kang; D B Schneider; Z Lin; D Hanahan; D A Dichek; P G Stock; S Baekkeskov
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

Review 5.  An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome.

Authors:  S E Straus; M Sneller; M J Lenardo; J M Puck; W Strober
Journal:  Ann Intern Med       Date:  1999-04-06       Impact factor: 25.391

6.  Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway.

Authors:  N Favre-Felix; A Fromentin; A Hammann; E Solary; F Martin; B Bonnotte
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

Review 7.  Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  2000-10       Impact factor: 7.486

8.  Suppression of Fas expression and down-regulation of Fas ligand in highly aggressive human thyroid carcinoma.

Authors:  F Basolo; L Fiore; A Baldanzi; R Giannini; M Dell'Omodarme; G Fontanini; F Pacini; R Danesi; P Miccoli; A Toniolo
Journal:  Lab Invest       Date:  2000-09       Impact factor: 5.662

9.  Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses.

Authors:  M Rescigno; V Piguet; B Valzasina; S Lens; R Zubler; L French; V Kindler; J Tschopp; P Ricciardi-Castagnoli
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

10.  Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells.

Authors:  G B Ragnarsson; E K Mikaelsdottir; H Vidarsson; J G Jónasson; K Olafsdóttir; K Kristjánsdóttir; J Kjartansson; H M Ogmundsdóttir; T Rafnar
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640
View more
  15 in total

Review 1.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 2.  Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer.

Authors:  Colin Sheehan; Crislyn D'Souza-Schorey
Journal:  J Cell Sci       Date:  2019-10-15       Impact factor: 5.285

Review 3.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.

Authors:  Jie-Hui Li; Dalia Rosen; Paul Sondel; Gideon Berke
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

Review 5.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

Review 6.  Assumptions of the tumor 'escape' hypothesis.

Authors:  Nicholas P Restifo; Paul A Antony; Steven E Finkelstein; Wolfgang W Leitner; Deborah P Surman; Marc R Theoret; Christopher E Touloukian
Journal:  Semin Cancer Biol       Date:  2002-02       Impact factor: 15.707

7.  Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system.

Authors:  Xiao-Zhong Wang; Xiao-Chun Chen; Yun-Xin Chen; Li-Juan Zhang; Dan Li; Feng-Lin Chen; Zhi-Xin Chen; Hong-Ying Chen; Qi-Ming Tao
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

8.  Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.

Authors:  Jie Hui Li; Martin S Kluger; Lisa A Madge; Lian Zheng; Alfred L M Bothwell; Jordan S Pober
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

9.  Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver.

Authors:  Hanchen Li; Xueli Fan; Calin Stoicov; Jian Hua Liu; Sharif Zubair; Elena Tsai; Ronald Ste Marie; Timothy C Wang; Stephen Lyle; Evelyn Kurt-Jones; Jeanmarie Houghton
Journal:  Gastroenterology       Date:  2009-06-12       Impact factor: 22.682

10.  Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.

Authors:  Giovanna Andreola; Licia Rivoltini; Chiara Castelli; Veronica Huber; Paola Perego; Paola Deho; Paola Squarcina; Paola Accornero; Francesco Lozupone; Luana Lugini; Annarita Stringaro; Agnese Molinari; Giuseppe Arancia; Massimo Gentile; Giorgio Parmiani; Stefano Fais
Journal:  J Exp Med       Date:  2002-05-20       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.